AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05177185 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
Study NCT05419934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Description: Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization.
Study NCT05419934 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Routine Care
Description: Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
Study NCT05335096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
Study NCT05335096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
Study NCT05287568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Study NCT05718934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine and glycopyrrolate
Description: See arm descriptions
Study NCT05718934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: See arm descriptions
Study NCT05287568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
Study NCT05464914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEO Pack
Description: is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
Study NCT06256679 — intervention group
Intervention type: PROCEDURE
Intervention: superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation
Description: The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
Study NCT06256679 — intervention group
Intervention type: PROCEDURE
Intervention: superior hypogastric plexus pulsed radiofrequency
Description: The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds.
Study NCT06165887 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention will be implemented.
Study NCT05047224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-assessment + in-person assessment
Description: Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
Study NCT05047224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-assessment only
Description: Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
Study NCT05494437 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PP-01 High Dose
Description: Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
Study NCT05177679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active supplement
Description: Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
Study NCT05177679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control supplement
Study NCT05494437 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PP-01 Low Dose
Description: CB1 partial agonist / GABAergic modulator
Study NCT05494437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT05494437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: CB1 receptor
Study NCT05494437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: GABAergic modulator
Study NCT05169606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Flossing
Description: Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
Study NCT05169606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretch
Description: AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release.
Study NCT05169606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
Study NCT04930887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel (Bupivacaine Liposome)
Description: Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
Study NCT04930887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
Study NCT06225726 — intervention group
Intervention type: PROCEDURE
Intervention: urethral bladder resection
Description: urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
Study NCT04862156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion (NMP)
Description: Storage and transportation of the donated liver using the OrganOx metra device.
Study NCT05203263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810A-v1) device prototype
Description: Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
Study NCT05203263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810B-v1) device prototype
Description: Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
Study NCT05203263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810C-v1) device prototype
Description: Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
Study NCT05203263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (810C-v1) device prototype
Description: Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
Study NCT05059444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
Study NCT04852887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Description: Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator.
Study NCT04852887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Description: Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
Study NCT05085496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05085496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05135494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
Study NCT05135494 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
Study NCT06212960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP712
Description: Clostridium botulinum Toxin
Study NCT06212960 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Clostridium botulinum Toxin
Study NCT05359094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
Study NCT05359094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
Study NCT05426694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular clock exercises
Description: In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
Study NCT05426694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises
Description: Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
Study NCT05426694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and strengthening exercises
Description: Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
Study NCT06012071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia dental implants
Description: Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
Study NCT06012071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia dental implants
Description: Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
Study NCT04752826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1808
Description: BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.
Study NCT04752826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Description: Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study NCT05618561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
Description: Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
Study NCT06080789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABI-767
Description: 125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
Study NCT06315335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Study NCT06315335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
Study NCT06359080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
Study NCT06239103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy
Description: Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
Study NCT06239103 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment, using the same PEMF device
Study NCT04997525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Combined with progesterone
Study NCT04997525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Combined with estradiol
Study NCT04997525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Description: Combined with hCG
Study NCT04997525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorionic Gonadotropin, Alpha
Description: In either natural cycle or combined with Follitropin Alfa
Study NCT04467034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stanford Tobacco Prevention Toolkit curriculum
Description: Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
Study NCT05664412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: at-home tACS using Starstim-Home tES
Description: We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
Study NCT05664412 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: at-home tACS using Starstim-Home tES
Description: We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
Study NCT06237335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT2100
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
Study NCT06237335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
Study NCT06332495 — intervention group
Intervention type: OTHER
Intervention: Questioning the patient during hygiene care
Description: The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
Study NCT05248347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)
Description: Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.